The role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in patients with Covid-19: a narrative review
DOI:
https://doi.org/10.24220/2318-0897v30e2021a5035Keywords:
Antihypertensive agents, Hypertension, Coronavirus infections, Angiotensin-converting enzyme inhibitors, Renin-angiotensin system, Sars virus.Abstract
The objective of this work is to gather and discuss the main scientific findings, opinions and specialists in medical communities and respect for the continuation of treatment with antihypertensive drugs in hypertensive patients diagnosed with Covid-19. This is a narrative review of the literature, restricted to publications until April 2020, using Medline and Embase as a database and consulting four scientific societies of cardiology. A total of 93 publications were found in the databases consulted and of these, 9 publications were eligible for analysis, with six publications being considered favorable for the continuation of treatment with angiotensin-converting enzyme inhibitors and receptor antagonists angiotensin, which met the decisions of cardiology societies; three other publications suggested that these classes of antihypertensives may increase the severity of the infection. The continuation of treatment with antihypertensive drugs during a coronavirus pandemic or after the diagnosis of infection presents a paradox between the potential increase in viral pathogenicity and the pulmonary protection provided by
the balance of the renin-angiotensin system.
Downloads
References
World Health Organization. Coronavirus disease (COVID-19) Pandemic. Geneva: Organization; 2020 [cited 2020 Apr 13]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74. https://doi.org/10.1016/S0140-
(20)30251-8
Wan Y, Shang J, Graham R, Baric RS, Fang L. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94(7):1-9. https://doi.org/10.1128/JVI.00127-20
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-6. https://doi.org/10.1038/nature03712
Santos RAS, Simões AC, Maric C, Silva DMR, Machado RP, Buhr ID, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Nat Acad Sci. 2003;100(14):8258-63. https://doi.org/10.1073/pnas.1432869100
Liu Z, Bing X, Zhi XZ. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41(2):145-51. https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet. 2020;8(4):1. https://doi.org/10.1016/S2213-2600(20)30116-8
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):1-2. https://doi.org/10.1093/jtm/taaa041
Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19 clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. Br Med J. 2020;369:1-2.https://doi.org/10.1136/bmj.m1313
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537-40. https://doi.org/10.1002/ddr.21656
Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74. https://doi.org/10.1007/s11427-020-1643-8
Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201(11):1380-8. https://doi.org/10.1164/rccm.202002-0445OC
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):756-60. https://doi.org/10.1080/22221751.2020.1746200
Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 Pandemic. Hypertension. 2020;75:1382-5. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. Am Soc Microbiol. 2020;11(2):1-3. https://doi.org/10.1128/mBio.00398-20
Strabelli TMV, Uip DE. COVID-19 e o coração. São Paulo: Sociedade Brasileira de Cardiologia; 2020 [citado 14 abr 2020]. Disponível em: https://www.scielo.br/pdf/abc/2020nahead/0066-782X-abc-20200209.pdf
Canadian Cardiovascular Society. COVID-19 and concerns regarding use of ACEi/ARB/ARNi medications for heart failure or hypertension. Ottawa: Society; 2020 [cited 2020 Apr 14]. Available from: https://www.conferenceharvester.com/Uploads/Documents/9006/CCSCHFSstatementregardingCOVID.pdf
Oren O, Kopecky SL, Gluckman TJ, Gersh BJ, Blumenthal RS. Coronavirus disease 2019 (COVID-19): epidemiology, clinical spectrum and implications for the cardiovascular clinician. J Am Coll Cardiol. 2020 [cited 2020 Apr 14]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/04/06/11/08/covid-19-epidemiology-clinical-spectrumand-implications-for-the-cv-clinician
European Society of Cardiology. Position Statement of the ESC Council on hypertension on ACE- inhibitors and angiotensin receptor blockers. Sophia Antipolis: Society; 2020 [cited 2020 Apr 14]. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-CHT)/News/position-statement-of-the-esc-council-on-hypertensionon-
ace-inhibitors-and-ang
Santos L, Torriani MS, Barros E. Medicamentos na prática da farmácia clínica. Porto Alegre: Artmed; 2013.
Lombardi NF, Eduardo A, Mendes M, Lucchetta RC, Luiza M, Fávero D, et al. Análise das discrepâncias encontradas durante a conciliação medicamentosa na admissão de pacientes em unidades de cardiologia: um estudo descritivo. Rev Lat Am Enferm. 2016;24(2760):1-7. https://doi.org/10.1590/1518-8345.0820.2760
